The 2005 amendment to Section 3(d) of the Indian Patents Act, 1970, emerged from India's need to balance TRIPS compliance with public health priorities, establishing a crucial framework against pharmaceutical evergreening practices.

Background and Circumstances Leading to Amendment

• TRIPS Compliance Pressure: India faced international pressure to align patent laws with WTO's Trade-Related Aspects of Intellectual Property Rights Agreement by 2005
• Public Health Concerns: Need to prevent "evergreening" - filing patents for minor modifications of existing drugs to extend monopoly periods
• Generic Industry Protection: Safeguarding India's position as "pharmacy of the developing world" producing affordable medicines
• Pharmaceutical Lobbying: Intense negotiations between innovator companies seeking stronger patents and generic manufacturers advocating accessibility
• Legislative Balance: Amendment required new forms of known substances to demonstrate "enhanced efficacy" for patent eligibility

Supreme Court's Application in Novartis Case (2013)

Legal Interpretation

• Novartis AG v. Union of India became the landmark case testing Section 3(d)'s constitutional validity and interpretation
• Court rejected patent application for Glivec (Imatinib Mesylate), a cancer drug, despite Novartis claiming improved bioavailability
• Therapeutic Efficacy Standard: Court established that "efficacy" means therapeutic efficacy, not mere physico-chemical improvements

Key Judicial Findings

• Beta Crystalline Form: Novartis's new salt form showed better flow properties and stability but lacked proven therapeutic superiority
• Burden of Proof: Patent applicant must demonstrate significant therapeutic enhancement over known substance
• Anti-Evergreening Victory: Decision effectively prevented frivolous patent extensions on existing drugs

Advantages of the Supreme Court Decision

Public Health Benefits

• Affordable Access: Glivec's monthly cost reduced from ₹1.2 lakh to ₹10,000, making life-saving cancer treatment accessible
• Generic Competition: Enabled multiple Indian companies to produce affordable versions, benefiting thousands of patients
• Global Impact: Strengthened access to essential medicines in developing countries dependent on Indian generics

Economic and Industry Benefits

• Generic Sector Growth: Protected India's $50 billion pharmaceutical industry and export capabilities
• Innovation Direction: Encouraged genuine pharmaceutical innovation rather than incremental modifications
• Legal Precedent: Created strong jurisprudence against patent evergreening practices

Disadvantages and Concerns

Investment and Innovation Challenges

• R&D Deterrent: May discourage multinational pharmaceutical companies from investing in Indian research facilities
• Technology Transfer: Potential reduction in advanced technology transfer and collaborative research programs
• Patent Uncertainty: Created perception of weak IP protection, affecting India's innovation ecosystem

International Relations Impact

• Trade Relations: Strained relationships with developed countries advocating stronger patent protection
• WTO Compliance: Ongoing debates about India's interpretation of TRIPS obligations
• Investment Climate: Concerns about intellectual property protection affecting foreign direct investment

The Novartis judgment represents a balanced approach prioritizing public health while maintaining innovation incentives. Future policy must strengthen indigenous pharmaceutical research through initiatives like PM-JADIR and National Biopharma Mission while ensuring affordable healthcare access remains protected.